The first medical device that monitors your immune system non-invasively
In Leuko Labs, we identified a crucial medical need: to avoid the serious infections that frequently occur in cancer patients treated with chemotherapy. Indeed, white-blood-cell levels can drastically and unexpectedly decrease in chemotherapy patients, which causes substantial risks of infections: 20% of these patients will catch an infection during their treatment, which requires 8-to-9-day hospitalizations costing 20.000€ per case. If critically low white-blood-cell levels could be detected in time, infection episodes could be avoided via the administration of prophylactic antibiotics. With current technology, however, the practical frequency of monitoring is severely limited because the measurement of white-blood-cell requires blood draws performed by medical personnel. In Leuko Labs, we addressed this issue by developing a new device that can detect low levels of white blood cells non-invasively, thus enabling patients and oncologists to access critical information and make the best decisions.
We devised a portable microscope prototype that acquires videos of capillary blood flow through the skin of patients in the finger nail-fold area.
In these videos, transparent particles that flow through the capillaries can be observed, tracked, and analyzed through proprietary software, which allows to obtain an estimate of the white-blood-cell level in a human subject.
Our prototype has been tested on 45 chemotherapy patients. It yielded promising results for the identification of patients with severely low white-blood-cell levels.
“This device–which has already been tested in 45 patients–will be able to quickly measure your white-blood-cell levels from home without requiring a single drop of your blood”
Healthcare system / Insurance companies
In Europe, 1.5 million patients start a chemotherapy treatment each year. Assuming a 50€ cost per daily measurement and average chemotherapies of 16 weeks, the total available market amounts to 1.2 billion euros.
Healthcare system/Insurance companies
Hospitalizations due to infections amount to 20.000€. Approx. 250.000 patients per year are hospitalized due to an infection, resulting in a burden of 5 billion euros per year to the European healthcare system.
Currently, only 1/3 of chemotherapy patients are administered colony-stimulating factors. Our device will allow to identify patients at risk in a personalized manner, thus increasing these drugs’ market share (e.g., Neulasta, Amgen) to the whole patient population.
“Improving the quality of life through this device would constitute a substantial added value both for clinicians and patients”
Leuko Labs Contact
Carlos Castro Gonzalez; e: firstname.lastname@example.org
Aurélien Bourquard; e:email@example.com
Innovation, Commercialization and Entrepreneurship Area
Centre of Support for Technological Innovation – UPM